Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy

被引:17
作者
Zhou, Li-Xin [1 ]
Li, Tao [1 ]
Huang, Yi-Ran [1 ]
Sha, Jian-Jun [1 ]
Sun, Peng [1 ]
Li, Dong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Urol, Shanghai 200127, Peoples R China
关键词
biochemical recurrence; histone modification; immunohistochemistry; prostate cancer; radical prostatectomy; tissue microarray; CANCER; EPIGENETICS; DIAGNOSIS; PATTERNS; SURVIVAL; HYPERMETHYLATION; DEACETYLATION; ACETYLATION; DISEASE; MARKERS;
D O I
10.1038/aja.2009.81
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
The role of histone modifications in the development and progression of cancer remains unclear. Here, we gave an investigation of the relationship between the various histone modifications and the risk prediction of the biochemical recurrence after radical prostatectomy (RP). Histone 3 lysine 4 dimethylation (H3K4diMe), trimethylation (H3K4triMe), lysine 36 trimethylation (H3K36triMe), histone 4 lysine 20 trimethylation (H4K20triMe) and acetylation of histome 3 lysine 9 (H3K9Ac) were evaluated using immnuohistochemistry coupled with the tissue microarray technique in 169 primary prostatectomy tissue samples. Recursive partitioning analysis (RPA) was used to analyze the data. Through global histone modification analysis in patients who underwent radical prostatectomy, we found that H3K4triMe can predict the risk of the biochemical recurrence for the low grade prostate cancer (Gleason score <= 6) after RP. In the case of high grade prostate cancer (Gleason score >= 7), H4K20triMe and H3K9Ac accompanying with the pre-operation prostate-specific antigen (PSA) level could also predict the risk of the biochemical recurrence after RP. In combination with the Gleason score and pre-operation PSA level, the acetylation and methylation of histones H3 and H4 can predict the biochemical recurrence of the prostate cancer following RP.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 40 条
[1]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[2]   Management of recurrent disease after radical prostatectomy [J].
Bott, SRJ .
PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (03) :211-216
[3]   Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis [J].
Brenner, H .
LANCET, 2002, 360 (9340) :1131-1135
[4]   The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia [J].
Dobosy, Joseph R. ;
Roberts, J. Lea W. ;
Fu, Vivian X. ;
Jarrard, David F. .
JOURNAL OF UROLOGY, 2007, 177 (03) :822-831
[5]   Epigenetic aberrations and cancer [J].
Ducasse, Miryam ;
Brown, Mark A. .
MOLECULAR CANCER, 2006, 5 (1)
[6]   Molecular origins of cancer: Epigenetics in cancer [J].
Esteller, Manel .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1148-1159
[7]   The epigenetic progenitor origin of human cancer [J].
Feinberg, AP ;
Ohlsson, R ;
Henikoff, S .
NATURE REVIEWS GENETICS, 2006, 7 (01) :21-33
[8]   Timeline - The history of cancer epigenetics [J].
Feinberg, AP ;
Tycko, B .
NATURE REVIEWS CANCER, 2004, 4 (02) :143-153
[9]   Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy [J].
Freedland, SJ ;
Humphreys, EB ;
Mangold, LA ;
Eisenberger, M ;
Dorey, FJ ;
Walsh, PC ;
Partin, AW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04) :433-439
[10]   Risk factors for extubation failure in patients following a successful spontaneous breathing trial [J].
Frutos-Vivar, Fernando ;
Ferguson, Niall D. ;
Estaban, Andres ;
Epstein, Scott K. ;
Arabi, Yaseen ;
Apezteguia, Carlos ;
Gonzalez, Marco ;
Hill, Nichola S. ;
Nava, Stefano ;
D'Empaire, Gabriel ;
Anzueto, Antonio .
CHEST, 2006, 130 (06) :1664-1671